Frontotemporal Dementia (FTD)


To inquire about your eligibility to enroll in one of our clinical trials, please email or call our clinic’s front office at 713-486-0500 and ask to speak to a research coordinator.

Collaborative Studies with Pharmaceutical Companies

A Phase 1B, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered into the Cisterna Magna (ICM) of Adult Subjects with Frontotemporal Dementia (FTD) and Mutations in the Progranulin Gene (GRN) (Passage Bio)
The purpose of this study is to assess the safety, tolerability and pharmacodynamics of PBFT02 in adult subjects with Frontotemporal Dementia (FTD) with the Progranulin (GRN) gene mutation. Gene therapy is an experimental technique that aims to replace the gene that is not working properly with a version of the gene that is normal.

  • Patients with early stage symptomatic Frontotemporal Dementia (FTD) are invited to participate
  • Sponsored by Passage Bio
  • Age: 35 to 75 years
  • Requires Study Partner
  • Multiple MRIs and lumbar punctures are required
  • Study will last for 5 years

Principal Investigator: Dr. Paul Schulz